English
Insider transactions
EDGARImmunome, Inc.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-16.
- Open-market purchases (code P)
- 11 transactions, 111,468 shares
- Sum of shares × price per share: 2,305,989.79
- Open-market sales (code S)
- 28 transactions, 1,228,648 shares
- Sum of shares × price per share: 27,508,460.88
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–50 of 86
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-11 Filed 2026-09-15 | Higgins Jack Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 18,000 | 1.35 | 24,300Derived: shares × price per share. Exact value 24300.00. | 78,250 | Direct (D) | Yes | — | Open filing 0001993684-26-000008 Read from the filing’s XML Dispute this row |
| 2026-09-11 Filed 2026-09-15 | Higgins Jack Officer: Chief Scientific Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 13,200 | 25.32 | 334,224Derived: shares × price per share. Exact value 334224.00. | 65,050 | Direct (D) | Yes | F1
| Open filing 0001993684-26-000008 Read from the filing’s XML Dispute this row |
| 2026-09-11 Filed 2026-09-15 | Higgins Jack Officer: Chief Scientific Officer | GBona fide gift | Disposed (D) | 8,800 | 0 | — | 56,250 | Direct (D) | Yes | — | Open filing 0001993684-26-000008 Read from the filing’s XML Dispute this row |
| 2026-09-11 Filed 2026-09-15 | Higgins Jack Officer: Chief Scientific Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 18,000 | 0 | — | 133,840 | Direct (D) | Yes | F3
| Open filing 0001993684-26-000008 Read from the filing’s XML Dispute this row |
| 2026-08-12 Filed 2026-08-12 | Barchas Isaac Director | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 11,048 | 27.25 | 301,058Derived: shares × price per share. Exact value 301058.00. | 92,211 | Direct (D) | Yes | F5
| Open filing 0001808343-26-000010 Read from the filing’s XML Dispute this row |
| 2026-08-11 Filed 2026-08-12 | Barchas Isaac Director | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 62,291 | 26.23 | 1,633,892.93Derived: shares × price per share. Exact value 1633892.93. | 0 | Indirect (I) See footnote | Yes | F1, F4, F3
| Open filing 0001808343-26-000010 Read from the filing’s XML Dispute this row |
| 2026-08-10 Filed 2026-08-12 | Barchas Isaac Director | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 10,125 | 26.07 | 263,958.75Derived: shares × price per share. Exact value 263958.75. | 62,291 | Indirect (I) See footnote | Yes | F1, F2, F3
| Open filing 0001808343-26-000010 Read from the filing’s XML Dispute this row |
| 2026-08-07 Filed 2026-08-10 | Barchas Isaac Director | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 15,248 | 26.06 | 397,362.88Derived: shares × price per share. Exact value 397362.88. | 72,416 | Indirect (I) See footnote | Yes | F1, F4, F3
| Open filing 0001808343-26-000009 Read from the filing’s XML Dispute this row |
| 2026-08-06 Filed 2026-08-10 | Barchas Isaac Director | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 20,840 | 26.06 | 543,090.4Derived: shares × price per share. Exact value 543090.40. | 87,664 | Indirect (I) See footnote | Yes | F1, F2, F3
| Open filing 0001808343-26-000009 Read from the filing’s XML Dispute this row |
| 2026-08-04 Filed 2026-08-06 | Horn Kinney Officer: CHIEF BUSINESS OFFICER | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 50,366 | 12.92 | 650,728.72Derived: shares × price per share. Exact value 650728.72. | 50,366 | Direct (D) | Yes | — | Open filing 0001831215-26-000005 Read from the filing’s XML Dispute this row |
| 2026-08-04 Filed 2026-08-06 | Horn Kinney Officer: CHIEF BUSINESS OFFICER | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 40,250 | 10.60 | 426,650Derived: shares × price per share. Exact value 426650.00. | 90,616 | Direct (D) | Yes | — | Open filing 0001831215-26-000005 Read from the filing’s XML Dispute this row |
| 2026-08-04 Filed 2026-08-06 | Horn Kinney Officer: CHIEF BUSINESS OFFICER | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 90,616 | 25.09 | 2,273,555.44Derived: shares × price per share. Exact value 2273555.44. | 0 | Direct (D) | Yes | F1, F2
| Open filing 0001831215-26-000005 Read from the filing’s XML Dispute this row |
| 2026-08-04 Filed 2026-08-06 | Horn Kinney Officer: CHIEF BUSINESS OFFICER | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 50,366 | 0 | — | 78,542 | Direct (D) | Yes | F3
| Open filing 0001831215-26-000005 Read from the filing’s XML Dispute this row |
| 2026-08-04 Filed 2026-08-06 | Horn Kinney Officer: CHIEF BUSINESS OFFICER | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 40,250 | 0 | — | 120,750 | Direct (D) | Yes | F4
| Open filing 0001831215-26-000005 Read from the filing’s XML Dispute this row |
| 2026-07-23 Filed 2026-07-27 | Stoneman Sandra G. Officer: CHIEF LEGAL OFFICER GC | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 38,250 | 0 | — | 43,805 | Direct (D) | No | F1
| Open filing 0001831144-26-000002 Read from the filing’s XML Dispute this row |
| 2026-07-23 Filed 2026-07-27 | Stoneman Sandra G. Officer: CHIEF LEGAL OFFICER GC | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 76,500 | 0 | — | 76,500 | Direct (D) | No | F2
| Open filing 0001831144-26-000002 Read from the filing’s XML Dispute this row |
| 2026-07-23 Filed 2026-07-27 | Tsai Philip Officer: Chief Technical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 38,250 | 0 | — | 81,550 | Direct (D) | No | F1
| Open filing 0002026600-26-000002 Read from the filing’s XML Dispute this row |
| 2026-07-23 Filed 2026-07-27 | Tsai Philip Officer: Chief Technical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 76,500 | 0 | — | 76,500 | Direct (D) | No | F2
| Open filing 0002026600-26-000002 Read from the filing’s XML Dispute this row |
| 2026-07-23 Filed 2026-07-27 | Horn Kinney Officer: CHIEF BUSINESS OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 31,250 | 0 | — | 31,250 | Direct (D) | No | F1
| Open filing 0001831215-26-000004 Read from the filing’s XML Dispute this row |
| 2026-07-23 Filed 2026-07-27 | Horn Kinney Officer: CHIEF BUSINESS OFFICER | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 62,500 | 0 | — | 62,500 | Direct (D) | No | F2
| Open filing 0001831215-26-000004 Read from the filing’s XML Dispute this row |
| 2026-07-23 Filed 2026-07-27 | Rosett Max Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 47,250 | 0 | — | 101,287 | Direct (D) | No | F1
| Open filing 0001994071-26-000006 Read from the filing’s XML Dispute this row |
| 2026-07-23 Filed 2026-07-27 | Rosett Max Officer: Chief Financial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 94,500 | 0 | — | 94,500 | Direct (D) | No | F2
| Open filing 0001994071-26-000006 Read from the filing’s XML Dispute this row |
| 2026-07-23 Filed 2026-07-27 | Lechleider Robert Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 54,000 | 0 | — | 69,805 | Direct (D) | No | F1
| Open filing 0001997584-26-000006 Read from the filing’s XML Dispute this row |
| 2026-07-23 Filed 2026-07-27 | Lechleider Robert Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 108,000 | 0 | — | 108,000 | Direct (D) | No | F2
| Open filing 0001997584-26-000006 Read from the filing’s XML Dispute this row |
| 2026-07-23 Filed 2026-07-27 | SIEGALL CLAY B Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 180,000 | 0 | — | 870,704 | Direct (D) | No | F1
| Open filing 0001167496-26-000005 Read from the filing’s XML Dispute this row |
| 2026-07-23 Filed 2026-07-27 | SIEGALL CLAY B Director · Officer: President and CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 360,000 | 0 | — | 360,000 | Direct (D) | No | F2
| Open filing 0001167496-26-000005 Read from the filing’s XML Dispute this row |
| 2026-07-23 Filed 2026-07-27 | Higgins Jack Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 38,250 | 0 | — | 60,250 | Direct (D) | No | F1
| Open filing 0001993684-26-000006 Read from the filing’s XML Dispute this row |
| 2026-07-23 Filed 2026-07-27 | Higgins Jack Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 76,500 | 0 | — | 76,500 | Direct (D) | No | F3
| Open filing 0001993684-26-000006 Read from the filing’s XML Dispute this row |
| 2026-07-07 Filed 2026-07-09 | Horn Kinney Officer: CHIEF BUSINESS OFFICER | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 1,092 | 12.92 | 14,108.64Derived: shares × price per share. Exact value 14108.64. | 1,092 | Direct (D) | Yes | — | Open filing 0001831215-26-000002 Read from the filing’s XML Dispute this row |
| 2026-07-07 Filed 2026-07-09 | Horn Kinney Officer: CHIEF BUSINESS OFFICER | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 1,092 | 25 | 27,300Derived: shares × price per share. Exact value 27300. | 0 | Direct (D) | Yes | F1
| Open filing 0001831215-26-000002 Read from the filing’s XML Dispute this row |
| 2026-07-07 Filed 2026-07-09 | Horn Kinney Officer: CHIEF BUSINESS OFFICER | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 1,092 | 0 | — | 128,908 | Direct (D) | Yes | F2
| Open filing 0001831215-26-000002 Read from the filing’s XML Dispute this row |
| 2026-07-07 Filed 2026-07-07 | Barchas Isaac Director | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 16,906 | 24.20 | 409,125.2Derived: shares × price per share. Exact value 409125.20. | 108,504 | Indirect (I) See footnote | Yes | F1, F4, F3
| Open filing 0001808343-26-000007 Read from the filing’s XML Dispute this row |
| 2026-07-06 Filed 2026-07-07 | Barchas Isaac Director | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 83,094 | 24.11 | 2,003,396.34Derived: shares × price per share. Exact value 2003396.34. | 125,410 | Indirect (I) See footnote | Yes | F1, F2, F3
| Open filing 0001808343-26-000007 Read from the filing’s XML Dispute this row |
| 2026-07-02 Filed 2026-07-07 | Lechleider Robert Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 55,000 | 8.73 | 480,150Derived: shares × price per share. Exact value 480150.00. | 70,805 | Direct (D) | Yes | — | Open filing 0001997584-26-000004 Read from the filing’s XML Dispute this row |
| 2026-07-02 Filed 2026-07-07 | Lechleider Robert Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 22,714 | 21.95 | 498,572.3Derived: shares × price per share. Exact value 498572.30. | 48,091 | Direct (D) | Yes | F1, F2
| Open filing 0001997584-26-000004 Read from the filing’s XML Dispute this row |
| 2026-07-02 Filed 2026-07-07 | Lechleider Robert Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 16,214 | 22.76 | 369,030.64Derived: shares × price per share. Exact value 369030.64. | 31,877 | Direct (D) | Yes | F1, F3
| Open filing 0001997584-26-000004 Read from the filing’s XML Dispute this row |
| 2026-07-02 Filed 2026-07-07 | Lechleider Robert Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 16,072 | 23.44 | 376,727.68Derived: shares × price per share. Exact value 376727.68. | 15,805 | Direct (D) | Yes | F1, F4
| Open filing 0001997584-26-000004 Read from the filing’s XML Dispute this row |
| 2026-07-02 Filed 2026-07-07 | Lechleider Robert Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 55,000 | 0 | — | 290,000 | Direct (D) | Yes | F5
| Open filing 0001997584-26-000004 Read from the filing’s XML Dispute this row |
| 2026-07-02 Filed 2026-07-02 | Barchas Isaac Director | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 75,665 | 22.35 | 1,691,112.75Derived: shares × price per share. Exact value 1691112.75. | 232,839 | Indirect (I) See footnote | Yes | F1, F6, F7
| Open filing 0001808343-26-000005 Read from the filing’s XML Dispute this row |
| 2026-07-02 Filed 2026-07-02 | Barchas Isaac Director | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 24,335 | 23.33 | 567,735.55Derived: shares × price per share. Exact value 567735.55. | 208,504 | Indirect (I) See footnote | Yes | F1, F8, F7
| Open filing 0001808343-26-000005 Read from the filing’s XML Dispute this row |
| 2026-06-30 Filed 2026-07-02 | Barchas Isaac Director | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 101,050 | 21.12 | 2,134,176Derived: shares × price per share. Exact value 2134176.00. | 308,504 | Indirect (I) See footnotes | Yes | F1, F2, F3, F4, F5
| Open filing 0001808343-26-000005 Read from the filing’s XML Dispute this row |
| 2026-06-25 Filed 2026-06-29 | Lechleider Robert Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 55,000 | 8.73 | 480,150Derived: shares × price per share. Exact value 480150.00. | 70,805 | Direct (D) | Yes | — | Open filing 0001997584-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-25 Filed 2026-06-29 | Lechleider Robert Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 40,580 | 19.56 | 793,744.8Derived: shares × price per share. Exact value 793744.80. | 30,225 | Direct (D) | Yes | F1, F2
| Open filing 0001997584-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-25 Filed 2026-06-29 | Lechleider Robert Officer: Chief Medical Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 14,420 | 20.66 | 297,917.2Derived: shares × price per share. Exact value 297917.20. | 15,805 | Direct (D) | Yes | F1, F3
| Open filing 0001997584-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-25 Filed 2026-06-29 | Lechleider Robert Officer: Chief Medical Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 55,000 | 0 | — | 345,000 | Direct (D) | Yes | F4
| Open filing 0001997584-26-000002 Read from the filing’s XML Dispute this row |
| 2026-06-15 Filed 2026-06-17 | Rosett Max Officer: Chief Financial Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Acquired (A) | 60,000 | 1.05 | 63,000Derived: shares × price per share. Exact value 63000.00. | 114,037 | Direct (D) | Yes | — | Open filing 0001994071-26-000004 Read from the filing’s XML Dispute this row |
| 2026-06-15 Filed 2026-06-17 | Rosett Max Officer: Chief Financial Officer | SOpen market or private sale of non-derivative or derivative security | Disposed (D) | 60,000 | 18.23 | 1,093,800Derived: shares × price per share. Exact value 1093800.00. | 54,037 | Direct (D) | Yes | F1, F2
| Open filing 0001994071-26-000004 Read from the filing’s XML Dispute this row |
| 2026-06-15 Filed 2026-06-17 | Rosett Max Officer: Chief Financial Officer | MExercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Disposed (D) | 60,000 | 0 | — | 0 | Direct (D) | Yes | F3
| Open filing 0001994071-26-000004 Read from the filing’s XML Dispute this row |
| 2026-06-10 Filed 2026-06-12 | WAGENHEIM PHILIP Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 9,897 | 0 | — | 9,897 | Direct (D) | No | F1
| Open filing 0001405684-26-000003 Read from the filing’s XML Dispute this row |
| 2026-06-10 Filed 2026-06-12 | BIENAIME JEAN JACQUES Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 9,897 | 0 | — | 9,897 | Direct (D) | No | F1
| Open filing 0001221590-26-000018 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| Vanguard Capital Management Common Stock | 5.04 | 5,725,578 | 09/30/2026 Filed 2026-10-30 | SCHEDULE 13G | Open filing 0002100119-26-001633 Dispute this row |
| T. Rowe Price Investment Management, Inc. COMMON STOCK | 17.4 | 19,676,883 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 2 | Open filing 0001897612-26-000609 Dispute this row |
| Sirenia Capital Management LP Common Stock, par value $0.0001 per share | 4.3 | 4,832,279.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0000919574-26-005205 Dispute this row |
| Alex Silverstein Common Stock, par value $0.0001 per share | 4.3 | 4,832,279.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0000919574-26-005205 Dispute this row |
| Sirenia Capital Management LP Common Stock, par value $0.0001 per share | 6.1 | 6,895,000.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G | Open filing 0000919574-26-003222 Dispute this row |
| Alex Silverstein Common Stock, par value $0.0001 per share | 6.1 | 6,895,000.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G | Open filing 0000919574-26-003222 Dispute this row |
| T. Rowe Price Investment Management, Inc. COMMON STOCK | 14.5 | 16,364,011 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 1 | Open filing 0001897612-26-000495 Dispute this row |
| Redmile Group, LLC Common Stock, $0.0001 par value per share | 4.9 | 5,558,885.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001104659-26-062570 Dispute this row |
| Jeremy C. Green Common Stock, $0.0001 par value per share | 4.9 | 5,558,885.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 4 | Open filing 0001104659-26-062570 Dispute this row |
| Point72 Asset Management, L.P. Common Stock, par value $0.0001 per share | 0 | 0.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 1 | Open filing 0000919574-26-003480 Dispute this row |
| Point72 Capital Advisors, Inc. Common Stock, par value $0.0001 per share | 0 | 0.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 1 | Open filing 0000919574-26-003480 Dispute this row |
| Steven A. Cohen Common Stock, par value $0.0001 per share | 0 | 0.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 1 | Open filing 0000919574-26-003480 Dispute this row |
| The Vanguard Group Common Stock | 0 | 0 | 03/13/2026 Filed 2026-03-26 | SCHEDULE 13G/AAmendment 3 | Open filing 0000102909-26-000422 Dispute this row |
| Redmile Group, LLC Common Stock, $0.0001 par value per share | 5.2 | 5,718,385.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 3 | Open filing 0001104659-26-016437 Dispute this row |
| Jeremy C. Green Common Stock, $0.0001 par value per share | 5.2 | 5,718,385.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 3 | Open filing 0001104659-26-016437 Dispute this row |
| Enavate Sciences GP, LLC Common Stock, par value $0.0001 per share | 4.3 | 4,768,583.00 | 12/18/2025 Filed 2025-12-22 | SCHEDULE 13D/AAmendment 2 | Open filing 0001953107-25-000019 Dispute this row |
| Immunome Aggregator, LP Common Stock, par value $0.0001 per share | 4.3 | 4,768,583.00 | 12/18/2025 Filed 2025-12-22 | SCHEDULE 13D/AAmendment 2 | Open filing 0001953107-25-000019 Dispute this row |
| T. Rowe Price Investment Management, Inc. COMMON STOCK | 12.2 | 10,644,674 | 10/31/2025 Filed 2025-11-07 | SCHEDULE 13G | Open filing 0001897612-25-000510 Dispute this row |
| FMR LLC COMMON STOCK | 15.0 | 13,056,709.11 | 09/30/2025 Filed 2025-10-07 | SCHEDULE 13G/AAmendment 1 | Open filing 0000315066-25-002307 Dispute this row |
| Abigail P. Johnson COMMON STOCK | 15.0 | 13,056,709.11 | 09/30/2025 Filed 2025-10-07 | SCHEDULE 13G/AAmendment 1 | Open filing 0000315066-25-002307 Dispute this row |
| FMR LLC COMMON STOCK | 7.1 | 6,167,666.00 | 06/30/2025 Filed 2025-08-06 | SCHEDULE 13G | Open filing 0000315066-25-002061 Dispute this row |
| Abigail P. Johnson COMMON STOCK | 7.1 | 6,167,666.00 | 06/30/2025 Filed 2025-08-06 | SCHEDULE 13G | Open filing 0000315066-25-002061 Dispute this row |
| The Vanguard Group Common Stock | 5.20 | 4,524,952 | 06/30/2025 Filed 2025-07-29 | SCHEDULE 13G | Open filing 0000932471-25-000844 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,092,408 filings read, dated 2004-06-14 to 2026-11-13: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 1 |
| 2016 | 204,322 |
| 2017 | 202,494 |
| 2018 | 202,048 |
| 2019 | 193,638 |
| 2020 | 144,184 |
| 2021 | 224,474 |
| 2022 | 40,015 |
| 2023 | 199,811 |
| 2024 | 185,386 |
| 2025 | 235,520 |
| 2026 | 254,737 |
Filings made before the SEC required XML are listed, not extracted.